Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (204)	12/13/1999 12:42:00 PM
From: Curtis E. Bemis	Read Replies (1) \| Respond to of 395

..what can happen when Rosenwald/Paramount/Aries buy up a big position in a tiny biotech company If I use Genta as the model for what can happen to Repligen, taking into consideration that Paramount already owns more than 10% of Repligen as of 12/10, I foresee the following- 1. They will take control of the company, change CEO and BOD Chair and replace with their own. 2. Tis not clear this is good for shareholders as GNTA seemed to improve on their own, from 2$ to over 6$ starting right after Nov 12 earnings report. 3. The outstanding shares are similar for both, 21M or so, but the float is 10X smaller for GNTA. That could suggest GNTA is easier to manipulate than RGEN. Don't see Rosenwald as a purchaser of RGEN yet, no Aries either. I guess that comes soon. Curt... (Am I on your wavelength now ?)